Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2017

View Archived Issues

Acorda Therapeutics decides to discontinue tozadenant development program

Desidustat approved as INN for Zydus Cadila's ZYAN-1

Lu-AA-41178 demonstrates efficacy in animal models of epilepsy, schizophrenia and depression

PledPharma and Solasia to develop and commercialize PledOxin Asia

Aurigene moves oral VISTA/VSIG8 antagonist AUPM-493 towards clinical development

Starpharma gives update on rolling NDA for VivaGel BV

FDA accepts, grants priority review to lofexidine NDA

gamma-Secretase modulator ACD-678 has properties supporting development for Alzheimer's disease

FDA approves Kaleo's Auvi-Q epinephrine autoinjector

BMS-986141 prevents arterial thrombosis in monkeys

Ardelyx discontinues development of RDX-7675

Catalyst Pharmaceuticals begins phase II proof-of-concept study of Firdapse

Phase III VITALITY-ALS study of tirasemtiv in ALS does not meet primary endpoint

Kaken Pharmaceutical evaluates novel prostanoid EP4 receptor antagonist for rheumatoid arthritis

EMA launches improved version of EudraVigilance system for safety monitoring

FDA gives orphan drug status to TRM-201 for hemophilic arthropathy

Immunovaccine and Leidos to develop malaria vaccine candidates

Janssen submits applications in U.S. and E.U. to expand approval of Darzalex

Sumitomo Dainippon Pharma and Angelini enter European license and distribution agreement for Latuda

Columbia University patents anti-RAGE antibodies

OriMabs presents new anti-PSMA antibodies for prostate cancer

Spingotec Therapeutics divulges DPP3 inhibitors

Dosing begins in registrational trial of derazantinib

Jiangsu MicroMedMark Biotech patents KRAS-targeting siRNAs for cancer

Menlo Therapeutics begins enrollment in PSORIXA study of serlopitant

Zebra Biologics and Scripps Research Institute disclose Trk-B agonist antibodies

Immunoproteasome inhibitor KZR-616 shows promise in phase I study

BARDA exercises option under Imvamune smallpox vaccine contract

FDA approves Juluca, the first two-drug regimen for treatment of HIV-1

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...